Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Clinigen Group plc
  6. Summary
    CLIN   GB00B89J2419

CLINIGEN GROUP PLC

(CLIN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
635.5(c) 645.5(c) 653(c) 659.5(c) 652.5(c) Last
361 135 217 810 186 843 297 716 165 573 Volume
+1.36% +1.57% +1.16% +1.00% -1.06% Change
More quotes
Estimated financial data (e)
Sales 2022 568 M 781 M 781 M
Net income 2022 39,5 M 54,3 M 54,3 M
Net Debt 2022 294 M 404 M 404 M
P/E ratio 2022 21,6x
Yield 2022 1,28%
Sales 2023 626 M 861 M 861 M
Net income 2023 50,5 M 69,5 M 69,5 M
Net Debt 2023 213 M 293 M 293 M
P/E ratio 2023 17,4x
Yield 2023 1,38%
Capitalization 868 M 1 195 M 1 194 M
EV / Sales 2022 2,05x
EV / Sales 2023 1,73x
Nbr of Employees 1 069
Free-Float 96,6%
More Financials
Company
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant... 
Sector
Biotechnology & Medical Research
Calendar
11/24 | 05:00amShareholder meeting
More about the company
Ratings of Clinigen Group plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about CLINIGEN GROUP PLC
10/08HUMANIGEN : Teams Up With Clinigen to Provide Managed Access Program for COVID-19 Drug Can..
MT
10/08CLINIGEN : Signs Exclusive Deal With Humanigen for Access to COVID-19 Treatment
MT
10/08CLINIGEN : Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in..
BU
09/22Secura Bio, Inc. Announces European Distribution Agreement for Copiktra with Clinigen G..
CI
09/17Clinigen Group Provides Information to the Shareholders
CI
09/16CLINIGEN : Slashes FY22 Guidance On Lower-Than-Expected H1 Leukemia Drug Sales
MT
09/16CLINIGEN : Pdf (664.26kb)
PU
09/16CLINIGEN : Earnings Flash (CLIN.L) CLINIGEN GROUP Reports FY21 EPS GBX29.80
MT
09/16Clinigen Group plc Reports Earnings Results for the Full Year Ended June 30, 2021
CI
09/02PRESS RELEASE : Paion signs exclusive uk supply and distribution agreement with clinigen
DJ
09/01FTSE 100 Rises, Fresh Brexit Concerns Could Lift Euro Vs Pound
DJ
09/01FTSE 100 Recovers From Tuesday's Losses
DJ
09/01CLINIGEN : New Clinigen Chairman Takes Office
MT
08/25CLINIGEN : CFO Steps Down; Interim Successor Named
MT
08/25Clinigen Group plc Announces Executive Changes
CI
More news
News in other languages on CLINIGEN GROUP PLC
10/08Humanigen s'associe à Clinigen pour fournir un programme d'accès géré au candidat médic..
10/08Clinigen signe un accord exclusif avec Humanigen pour l'accès au traitement COVID-19
09/16Clinigen Group revoit à la baisse ses prévisions pour l'exercice 22 en raison de ventes..
09/01Le nouveau président de Clinigen prend ses fonctions
06/09CLINIGEN GROUP PLC : -25% après une mauvaise surprise
More news
Analyst Recommendations on CLINIGEN GROUP PLC
More recommendations
Chart CLINIGEN GROUP PLC
Duration : Period :
Clinigen Group plc Technical Analysis Chart | CLIN | GB00B89J2419 | MarketScreener
Technical analysis trends CLINIGEN GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 652,50 GBX
Average target price 796,87 GBX
Spread / Average Target 22,1%
EPS Revisions
Managers and Directors
Shaun Edward Chilton Chief Executive Officer & Executive Director
Richard Paling Chief Financial Officer & Financial Controller
Elmar J. Schnee Independent Non-Executive Chairman
Ivo Timmermans Chief Medical Officer
Samuel Gordon Herbert Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
CLINIGEN GROUP PLC-3.33%1 195
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610